Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 556

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 5
Chunk 556
---
.2)    ​    (79,784)    ​    (9.5)    ​    (92,173)    ​   (21.6)
Other income/(expense)                                      42,598           6.8           39,933           4.8          (2,729)         (0.6)
Income tax (expense)/benefit                               (7,192)         (1.1)          (4,509)         (0.5)              283           0.1
Equity in earnings of equity investees, net of tax          46,469           7.4           47,295           5.6           49,753          11.7
Net income/(loss)                                           38,170           6.1          101,094          12.1        (360,386)        (84.5)
Net income /(loss) attributable to our company              37,729           6.0          100,780          12.0        (360,835)        (84.6)
​
Taxation
Cayman Islands
HUTCHMED (China) Limited is incorporated in the Cayman Islands. The Cayman Islands currently levies no taxes on profits, income, gains or appreciation earned by individuals or corporations. In addition, our payment of dividends, if any, is not subject to withholding tax in the Cayman Islands. For more information, see Item 10.E. “Taxation—Overview of Tax Implications of Various Other Jurisdictions—Cayman Islands Taxation.”
People’s Republic of China
Our subsidiaries and a joint venture incorporated in the PRC are governed by the EIT Law and regulations. Under the EIT Law, the standard EIT rate is 25% on taxable profits as reduced by available tax losses. Tax losses may be carried forward to offset any taxable profits for the following five years (extended to ten years for those with HNTE status, with effective from January 1, 2018). HUTCHMED Limited and our non-consolidated joint venture, Shanghai Hutchison Pharmaceuticals, have been successful in their respective applications to renew their HNTE status for three years from January 1, 2023 to December 31, 2025. Accordingly, these entities are eligible to a preferential EIT rate of 15% for the years ended/ending December 31, 202